- Report
- December 2022
- 153 Pages
Global
From €2507EUR$2,625USD£2,096GBP
€5014EUR$5,250USD£4,193GBP
- Report
- August 2023
- 240 Pages
Global
From €1901EUR$1,990USD£1,589GBP
- Report
- March 2022
- 175 Pages
Global
From €1901EUR$1,990USD£1,589GBP
- Report
- September 2024
- 150 Pages
China
From €5682EUR$5,950USD£4,752GBP
- Report
- November 2023
- 175 Pages
Global
From €4775EUR$5,000USD£3,993GBP
- Report
- September 2021
- 40 Pages
China
From €2483EUR$2,600USD£2,076GBP
- Report
- September 2021
- 40 Pages
China
From €2483EUR$2,600USD£2,076GBP
- Report
- July 2021
- 50 Pages
China
From €2483EUR$2,600USD£2,076GBP
From €2483EUR$2,600USD£2,076GBP
- Report
- June 2021
- 50 Pages
China
From €2483EUR$2,600USD£2,076GBP
- Report
- May 2021
- 50 Pages
China
From €2483EUR$2,600USD£2,076GBP
- Report
- April 2021
- 50 Pages
China
From €2483EUR$2,600USD£2,076GBP
- Report
- March 2024
- 92 Pages
Europe
From €3295EUR$3,450USD£2,755GBP
- Report
- March 2024
- 79 Pages
Africa, Middle East
From €3295EUR$3,450USD£2,755GBP
- Report
- March 2024
- 74 Pages
From €3295EUR$3,450USD£2,755GBP
- Report
- March 2024
- 118 Pages
Asia Pacific
From €3295EUR$3,450USD£2,755GBP
- Report
- March 2024
- 79 Pages
North America
From €3295EUR$3,450USD£2,755GBP
- Report
- October 2023
- 206 Pages
Global
From €4250EUR$4,450USD£3,554GBP
- Report
- July 2022
- 199 Pages
Global
From €4250EUR$4,450USD£3,554GBP
- Report
- November 2023
- 30 Pages
Global
From €2626EUR$2,750USD£2,196GBP

The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy.
The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments.
In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more